ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Atractylenolide III improves ovarian dysfunction and endometrial receptivity in a PCOS rat model by regulating Cybb-mediated oxidative stress.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Polycystic ovary syndrome (PCOS) is an endocrine and metabolic condition affecting reproductive health, marked by disrupted ovulation, excessive androgen levels, and impaired endometrial receptivity. Oxidative stress is an important part of its pathophysiological process. Atractylenolide III (ATIII), a major sesquiterpene lactone derived from Atractylodes macrocephala Koidz., exhibits antioxidant properties; however, its role and molecular mechanisms in PCOS have not yet been explored. A PCOS rat model was established using dehydroepiandrosterone (DHEA) and subsequently treated with ATIII or metformin. Estrous cycle, ovarian morphology, serum hormone levels, glucose metabolism, and endometrial receptivity markers were evaluated. Oxidative stress status was evaluated by detecting the levels of superoxide dismutase (SOD), malondialdehyde (MDA), and antioxidant-related genes and proteins expression. Ovarian transcriptomic sequencing was performed to explore potential molecular pathways associated with ATIII treatment. ATIII administration was associated with restoration of estrous cycle, reduction of cystic follicles, improvement of ovulation, and normalization of serum hormones and metabolic parameters in PCOS rats. Ovarian stromal fibrosis was attenuated, and morphological and molecular markers of endometrial receptivity were improved. ATIII treatment was accompanied by increased SOD activity, decreased MDA accumulation, and restoration of NRF2-related antioxidant genes and proteins. Transcriptomic analysis revealed enrichment of oxidative stress-related pathways, within which Cybb (encoding NOX2) was found as a differentially regulated gene that was upregulated in PCOS ovaries then reduced following ATIII treatment. ATIII improves reproductive and metabolic abnormalities and enhances endometrial receptivity in a PCOS rat model. These results are mediated by attenuation of ovarian oxidative stress and modulation of Cybb-related redox signaling. These data offer mechanistic insight into the pharmacological potential of ATIII in PCOS.
Indexed as
Identifiers
41910730What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.